IVAX Corporation (IVX) Receives Approval Of Ciprofloxacin Tablets
10/19/2005 5:11:43 PM
IVAX Corporation (AMEX:IVX), (LSE:IVX.L) has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin tablets in 250 mg, 500 mg and 750 mg strengths and tentative approval for the 100 mg strength. This product will be sold through the company's wholly owned subsidiary IVAX Pharmaceuticals, Inc. Ciprofloxacin is the generic equivalent of Cipro(R), which is an antibiotic marketed by Bayer Pharmaceuticals Corporation. U.S. sales of Cipro in the 250 mg, 500 mg and 750 mg dosage strengths were over $1.0 billion in 2003.
comments powered by